FibroGen, Inc. has announced the approval by the China State Administration for Market Regulation for the sale of FibroGen International (Hong Kong) Ltd. to AstraZeneca Treasury Limited. This approval is a key step in the transaction process, which was initially detailed in a Share Purchase Agreement dated February 20, 2025. The sale is on track to be finalized in the third quarter of 2025, pending the fulfillment of other contractual conditions and deliverables.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.